What about “Pharming”? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs
Abstract
:Funding
Conflicts of Interest
References
- Levine, D.A. “Pharming”: The abuse of prescription and over-the-counter drugs in teens. Curr. Opin. Paediatr. 2007, 19, 270–274. [Google Scholar] [CrossRef] [PubMed]
- Reeves, R.R.; Ladner, M.E.; Perry, C.L.; Burke, R.S.; Laizer, J.T. Abuse of medications that theoretically are without abuse potential. South. Med. J. 2015, 108, 151–157. [Google Scholar] [CrossRef] [PubMed]
- Schifano, F. Recent Changes in Drug Abuse Scenarios: The New/Novel Psychoactive Substances (NPS) Phenomenon. Brain Sci. 2018, 8, 221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schifano, F.; Chiappini, S.; Corkery, J.M.; Guirguis, A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sci. 2018, 8, 73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schifano, F. Coming off prescribed psychotropic medications: Insights from their use as recreational drugs. Psychother. Psychosom. 2020, 89, 274–282. [Google Scholar] [CrossRef] [PubMed]
- Coombes, H.; Cooper, R.J. Staff perceptions of prescription and over-the-counter drug dependence services in England: A qualitative study. Addict. Sci. Clin. Pract. 2019, 14, 41. [Google Scholar] [CrossRef] [PubMed]
- Lessenger, J.E.; Feinberg, S.D. Abuse of prescription and over-the-counter medications. J. Am. Board Fam. Med. 2008, 21, 45–54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lipari, R.N.; Williams, M.; Van Horn, S.L. Why do Adults Misuse Prescription Drugs? The CBHSQ Report: 27 July 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD. Available online: https://www.samhsa.gov/data/sites/default/files/report_3210/ShortReport-3210.html (accessed on 19 September 2020).
- Orsolini, L.; Papanti, G.D.; Francesconi, G.; Schifano, F. Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts. Cyberpsychol. Behav. Soc. Netw. 2015, 18, 296–300. [Google Scholar] [CrossRef] [PubMed]
- Hughes, A.; Williams, M.R.; Lipari, R.N.; Bose, J.; Copello, E.A.P.; Kroutil, L.A. Prescription Drug Use and Misuse in the United States: Results from the 2015 National Survey on Drug Use and Health. NSDUH Data Review. September 2016. Available online: https://samhsa.gov/data (accessed on 19 September 2020).
- Soussan, C.; Andersson, M.; Kjellgren, A. The diverse reasons for using Novel Psychoactive Substances—A qualitative study of the users’ own perspectives. Int. J. Drug Policy 2018, 52, 71–78. [Google Scholar] [CrossRef] [PubMed]
- Schifano, F.; Papanti, G.D.; Orsolini, L.; Corkery, J.M. The consequences of drug misuse on post-marketing surveillance. Exp. Rev. Clin. Pharmacol. 2016, 9, 867–871. [Google Scholar] [CrossRef] [Green Version]
- Alomar, M.; Tawfiq, A.M.; Hassan, N.; Palaian, S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: Current status, challenges and the future. Therap. Adv. Drug Saf. 2020. [Google Scholar] [CrossRef]
- Johanson, C.E.; Balster, R.L.; Henningfield, J.E.; Schuster, C.R.; Anthony, J.C.; Barthwell, A.G.; Coleman, J.J.; Dart, R.C.; Gorodetzky, C.W.; O’Keeffe, C.; et al. Risk management post-marketing surveillance for the abuse of medications acting on the central nervous system: Expert panel report. Drug Alcohol Depend. 2009, 105 (Suppl. 1), S65–S71. [Google Scholar] [CrossRef] [Green Version]
- Novak, S.P.; Håkansson, A.; Martinez-Raga, J.; Reimer, J.; Krotki, K.; Varughese, S. Nonmedical use of prescription drugs in the European Union. BMC Psychiatry 2016, 16, 274. [Google Scholar] [CrossRef] [Green Version]
- Throckmorton, D.C.; Gottlieb, S.; Woodcock, J. The FDA and the next wave of drug abuse—Proactive pharmacovigilance. N. Engl. J. Med. 2018, 379, 205–207. [Google Scholar] [CrossRef] [PubMed]
- Medicines and Healthcare Products Regulatory Agency—Gov.uk (MHRA). Yellow Card Scheme. Available online: https://yellowcard.mhra.gov.uk (accessed on 19 September 2020).
- European Medicines Agency (EMA) Guideline on Good Pharmacovigilance Practices (GVP) Annex I—Definitions (Rev 4) (2017). Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf (accessed on 19 September 2020).
- Schifano, F.; Napoletano, F.; Chiappini, S.; Guirguis, A.; Corkery, J.M.; Bonaccorso, S.; Ricciardi, A.; Scherbaum, N.; Vento, A. New/emerging psychoactive substances and associated psychopathological consequences. Psychol. Med. 2019, 87, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mackey, T.K.; Nayyar, G. Digital danger: A review of the global public health, patient safety and cybersecurity threats posed by illicit online pharmacies. Br. Med. Bull. 2016, 118, 110–126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Orsolini, L.; Papanti, D.; Corkery, J.; Schifano, F. An insight into the deep web; why it matters for addiction psychiatry? Hum. Psychopharmacol. Clin. Exp. 2017, 32, e2573. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Monteith, S.; Glenn, T. Searching online to buy commonly prescribed psychiatric drugs. Psychiatry Res. 2018, 260, 248–254. [Google Scholar] [CrossRef] [PubMed]
- Scherbaum, N.; Schifano, F.; Bonnet, U. New Psychoactive Substances (NPS)—A Challenge for the Addiction Treatment Services. Pharmacopsychiatry 2017, 50, 116–122. [Google Scholar] [CrossRef] [PubMed]
- Fingleton, N.; Duncan, E.; Watson, M.; Matheson, C. Specialist clinicians’ management of dependence on non-prescription medicines and barriers to treatment provision: An exploratory mixed methods study using behavioural theory. Pharmacy 2019, 7, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chiappini, S.; Schifano, F. What about “Pharming”? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs. Brain Sci. 2020, 10, 736. https://doi.org/10.3390/brainsci10100736
Chiappini S, Schifano F. What about “Pharming”? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs. Brain Sciences. 2020; 10(10):736. https://doi.org/10.3390/brainsci10100736
Chicago/Turabian StyleChiappini, Stefania, and Fabrizio Schifano. 2020. "What about “Pharming”? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs" Brain Sciences 10, no. 10: 736. https://doi.org/10.3390/brainsci10100736